Related Experiment Videos
Mezlocillin in the therapy of serious infections
Abstract:
Mezlocillin, a new semisynthetic penicillin chemically related to ampicillin which is more active than carbenicillin against Ps. aeruginosa, B. fragilis and Strep. faecalis and which inhibits many Klebsiella, was evaluated in the therapy of 34 episodes of infection in 26 patients. Infection sites included pulmonary, urinary tract and tissue infections, including peritonitis. Seven patients had bacteremia. Clinical cures were achieved in 83 per cent and bacteria cures in 76 per cent of infections. Cure was achieved with mezlocillin in patients with infections caused by carbenicillin-resistant species. Adverse effects of therapy were minimal, one rash and one episode of reversible neutropenia. Serum and body flevels of susceptible organisms.uid levels were easily maintained above the inhibitory levels of susceptible organisms. Mezlocillin was a safe, well tolerated and effective antibiotic in the treatment of infections due to susceptible organisms.
Insights
Mezlocillin, a potent penicillin antibiotic, effectively treated various infections, including those resistant to carbenicillin. This new drug demonstrated high cure rates with minimal adverse effects in patients.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Mezlocillin is a novel semisynthetic penicillin.
- It exhibits enhanced activity against specific Gram-negative and Gram-positive bacteria compared to carbenicillin.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of mezlocillin.
- To assess mezlocillin's effectiveness in treating diverse infections, including those caused by resistant pathogens.
Main Methods:
- A clinical trial involving 26 patients with 34 infection episodes.
- Infections included pulmonary, urinary tract, tissue, peritonitis, and bacteremia.
- Treatment outcomes and adverse effects were monitored.
Main Results:
- Achieved 83% clinical cure and 76% bacterial cure rates.
- Effective against infections caused by carbenicillin-resistant organisms.
- Therapy was well-tolerated with minimal adverse events like rash and reversible neutropenia.
Conclusions:
- Mezlocillin is a safe, well-tolerated, and effective antibiotic.
- It is suitable for treating infections caused by susceptible organisms.
- Demonstrated clinical utility, particularly against resistant strains.